ISBN: 978-1-4731-3093-7 Study Intervention and comparison (in HF clinic unless stated otherwise) Population Outcomes Comments with clinical monitoring Northstar trial: NP monitoring: Further investigation and treatment if months Clinical monitoring: Therapy intensified at clinician discretion according to clinical assessment, 30 months Age 18 years, LVEF 45 % Elevated NP (NT- ml) despite education on CHF and optimal ACE/ARB and BB therapy HTA IPD: Mortality by age all-cause admission by age Recruited from HF clinics OPTIMA trial: NP monitoring: Therapy intensified according to clinical status and serial BNP levels, 2 years Clinical monitoring: Therapy was intensified according to clinical status, 2 years Age limits 18-90, Recently hospitalised, NYHA III/IV and HTA: None Study papers: Mortality by age all-cause admission by age No informatio n on recruitmen t PRIMA trial: NP monitoring: therapy increased to reach or maintain target (NT-proBNP at the lowest level recorded at discharge or two weeks following), 24 months Clinical monitoring: Therapy increased at clinician s discretion according to clinical assessment, 24 months Age mean: 72(12) Recently hospitalised HF- admission, mainly NYHA III, Elevated NPs (NT- proBNP levels at admission 1700 pg/mL) that respond to treatment (decrease 10% at discharge) HTA aggregate: Mortality by age Troughton IPD: HF admission Recruited from hospital PROTECT trial: (Weiner , Mallick , Ibrahim , Bhardwaj , Bhardwaj )) NP monitoring: Therapy intensified to reach target (NT- months Clinical monitoring: Therapy intensified at clinician discretion according to clinical assessment, 6-12 months Age 21 years, NYHA class II-IV, LVEF 40%, destabilisation in (attended hospital or clinic for worsening HF) HTA: Nil Troughton IPD: HF hospitalisation Study papers: Quality of life Hypotension Recruited Chronic Heart Failure Monitoring NICE 2018. All rights reserved. Subject to Notice of rights. 